Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving
 patients treated with Secotex® (Tamsulosin) in "real life" settings. The aim of a PEM is to
 monitor the safety profile of Secotex® in a cohort of patients with Benign Prostatic
 Hyperplasia as used in general practice
Inclusion Criteria:

 -  Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH)
 and/or that, according to the Physician, their symptoms require medical treatment to
 improve their quality of life. The patients could be naïve to treatment or could be on
 treatment with other drugs but have not responded adequately to treatment. This study
 is non-interventional, so the decision to treat must be based on the best standard
 accepted clinical practice, and according to Secotex® prescribing information

 Exclusion Criteria:

 -  Patients with known hypersensitivity to Tamsulosin, or any other component of the
 product

 -  Patients with a history of orthostatic hypotension or severe liver failure